Humacyte, Inc. (HUMA) NASDAQ
0.79
+0.0883(+12.61%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.79
+0.0883(+12.61%)
Currency In USD
| Previous Close | 0.7 |
| Open | 0.71 |
| Day High | 0.82 |
| Day Low | 0.71 |
| 52-Week High | 2.93 |
| 52-Week Low | 0.55 |
| Volume | 4.02M |
| Average Volume | 6.77M |
| Market Cap | 123.58M |
| PE | -3.03 |
| EPS | -0.26 |
| Moving Average 50 Days | 0.9 |
| Moving Average 200 Days | 1.38 |
| Change | 0.09 |
Humacyte To Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Mar 02, 2026 1:00 PM GMT
DURHAM, N.C., March 02, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company’
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting
GlobeNewswire Inc.
Feb 18, 2026 1:00 PM GMT
- Data presented at Annual Winter Meeting 2026 for the Vascular & Endovascular Surgery Society - - After up to 36 months of follow-up, extremity arterial trauma patients had high rates of limb salvage, low rates of infection, and no unprovoked struc
Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels
GlobeNewswire Inc.
Feb 09, 2026 1:00 PM GMT
DURHAM, N.C., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the recently